Plexxikon, Roche to work together on new class of cancer drugs

10/9/2006 | American City Business Journals

Roche will pay up to $700 million to Calif.-based biotech Plexxikon to create a new early-stage cancer therapy based on the biotech's compound, which attracted a lot of attention. The drug selectively inhibits a genetic mutation, called B-RafV600E kinase, found in more than 70% of malignant melanomas and a large percentage of other cancers and tumor types.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI